Literature DB >> 17139666

Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study.

Rupa Bessant1, Rachel Duncan, Gareth Ambler, Jo Swanton, David A Isenberg, Caroline Gordon, Anisur Rahman.   

Abstract

OBJECTIVE: Patients with systemic lupus erythematosus (SLE) are significantly more likely to experience a myocardial infarction or a stroke than age-matched controls. We compared the prevalence of conventional and lupus-specific risk factors in patients with SLE just before a cardiovascular event and in matched controls with SLE but no cardiovascular disease (CVD).
METHODS: Twenty-nine patients with SLE and CVD were enrolled. For each patient, 2 ethnically- and sex-matched controls were obtained, 1 matched for age and 1 for SLE duration. Data regarding risk factors were collected for the time immediately preceding the relevant cardiovascular event, or at an equivalent time for controls.
RESULTS: Patients' median age at event was 49 years (interquartile range 43-54 years) and mean disease duration was 12.0 +/- 7.1 years. Patients with SLE and CVD were more likely than both age and duration controls to be treated for hypertension (P = 0.01 and P = 0.001, respectively) and to have elevated triglyceride levels (P = 0.05 and P = 0.01, respectively). Compared with duration controls, CVD patients were more likely to have lupus anticoagulant (P = 0.03), but less likely to be receiving treatment with hydroxychloroquine (P = 0.003). Compared with age controls, patients were more likely to be current smokers (P = 0.03), to have taken a mean dosage >7.5 mg/day of prednisolone (P = 0.04), and to have been treated with pulsed methylprednisolone (P = 0.03). In multivariable analysis, only hypertension treatment was an independent risk factor for CVD.
CONCLUSION: We identified significantly increased prevalence of some conventional and lupus-specific risk factors in patients with SLE immediately before a CVD event compared with controls matched for age or disease duration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17139666     DOI: 10.1002/art.22343

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  30 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

2.  The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model.

Authors:  Tamar R Aprahamian; Xuemei Zhong; Shahzada Amir; Christoph J Binder; Lo-Ku Chiang; Lamyaa Al-Riyami; Raffi Gharakhanian; Margaret M Harnett; William Harnett; Ian R Rifkin
Journal:  Int J Parasitol       Date:  2015-02-07       Impact factor: 3.981

Review 3.  The role of preventive cardiology in systemic lupus erythematosus.

Authors:  Jennifer Rae Elliott; Susan Manzi; Daniel Edmundowicz
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

4.  Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus.

Authors:  Laura J Julian; Chris Tonner; Ed Yelin; Jinoos Yazdany; Laura Trupin; Lindsey A Criswell; Patricia P Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

5.  Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus.

Authors:  Janet W Maynard; Hong Fang; Michelle Petri
Journal:  J Rheumatol       Date:  2012-03-01       Impact factor: 4.666

6.  Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus.

Authors:  D K Wells; M M Ward
Journal:  Clin Exp Rheumatol       Date:  2010-05-13       Impact factor: 4.473

7.  Ambulatory blood pressure and subclinical cardiovascular disease in patients with juvenile-onset systemic lupus erythematosus.

Authors:  Nur Canpolat; Ozgur Kasapcopur; Salim Caliskan; Selman Gokalp; Meltem Bor; Mehmet Tasdemir; Lale Sever; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2012-10-10       Impact factor: 3.714

8.  Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort.

Authors:  A M Bertoli; L M Vilá; G S Alarcón; G McGwin; J C Edberg; M Petri; R Ramsey-Goldman; J D Reveille; R P Kimberly
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

9.  Atherosclerosis risk factors in systemic lupus erythematosus.

Authors:  Surabhi Agarwal; Jennifer R Elliott; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

10.  Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort.

Authors:  Laura E Schanberg; Christy Sandborg; Huiman X Barnhart; Stacy P Ardoin; Eric Yow; Gregory W Evans; Kelly L Mieszkalski; Norman T Ilowite; Anne Eberhard; Deborah M Levy; Yukiko Kimura; Emily von Scheven; Earl Silverman; Suzanne L Bowyer; Lynn Punaro; Nora G Singer; David D Sherry; Deborah McCurdy; Marissa Klein-Gitelman; Carol Wallace; Richard Silver; Linda Wagner-Weiner; Gloria C Higgins; Hermine I Brunner; Lawrence Jung; Jennifer B Soep; Ann Reed
Journal:  Arthritis Rheum       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.